Cargando…
Licensed liposomal vaccines and adjuvants in the antigen delivery system
Liposomes (LSs) are promising nanoparticles with unique properties such as controlled nanosize, large surface area, increased reactivity, and ability to undergo modification. Worldwide, licensed liposomal forms of antibiotics, hormones, antioxidants, cytostatics, ophthalmic drugs, etc., are availabl...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837556/ https://www.ncbi.nlm.nih.gov/pubmed/36685697 http://dx.doi.org/10.5114/bta.2022.120709 |
_version_ | 1784869106745344000 |
---|---|
author | Krasnopolsky, Yuriy Pylypenko, Daria |
author_facet | Krasnopolsky, Yuriy Pylypenko, Daria |
author_sort | Krasnopolsky, Yuriy |
collection | PubMed |
description | Liposomes (LSs) are promising nanoparticles with unique properties such as controlled nanosize, large surface area, increased reactivity, and ability to undergo modification. Worldwide, licensed liposomal forms of antibiotics, hormones, antioxidants, cytostatics, ophthalmic drugs, etc., are available on the pharmaceutical market. This review focuses on the adjuvant properties of LSs in the production of vaccines (VACs). LS-VACs have the following advantages: antigens with low immunogenicity can become highly immunogenic; LSs can include both hydrophilic and hydrophobic antigens; LSs allow to achieve a prolonged specific action of antibodies; and LSs reduce the toxicity and pyrogenicity of encapsulated antigens and adjuvants. The immune response is influenced by the composition of the liposomal membrane, physicochemical characteristics of lipids, antigen localization in LSs, interaction of LSs with complement, and a number of proteins, which leads to opsonization. The major requirements for adjuvants are their ability to enhance the immune response, biodegradability, and elimination from the organism, and LSs fully meet these requirements. The effectiveness and safety of LSs as carriers in the antigen delivery system have been proven by the long-term clinical use of licensed vaccines against hepatitis A, influenza, herpes zoster, malaria, and COVID-19. |
format | Online Article Text |
id | pubmed-9837556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-98375562023-01-20 Licensed liposomal vaccines and adjuvants in the antigen delivery system Krasnopolsky, Yuriy Pylypenko, Daria BioTechnologia (Pozn) Review Papers Liposomes (LSs) are promising nanoparticles with unique properties such as controlled nanosize, large surface area, increased reactivity, and ability to undergo modification. Worldwide, licensed liposomal forms of antibiotics, hormones, antioxidants, cytostatics, ophthalmic drugs, etc., are available on the pharmaceutical market. This review focuses on the adjuvant properties of LSs in the production of vaccines (VACs). LS-VACs have the following advantages: antigens with low immunogenicity can become highly immunogenic; LSs can include both hydrophilic and hydrophobic antigens; LSs allow to achieve a prolonged specific action of antibodies; and LSs reduce the toxicity and pyrogenicity of encapsulated antigens and adjuvants. The immune response is influenced by the composition of the liposomal membrane, physicochemical characteristics of lipids, antigen localization in LSs, interaction of LSs with complement, and a number of proteins, which leads to opsonization. The major requirements for adjuvants are their ability to enhance the immune response, biodegradability, and elimination from the organism, and LSs fully meet these requirements. The effectiveness and safety of LSs as carriers in the antigen delivery system have been proven by the long-term clinical use of licensed vaccines against hepatitis A, influenza, herpes zoster, malaria, and COVID-19. Termedia Publishing House 2022-12-24 /pmc/articles/PMC9837556/ /pubmed/36685697 http://dx.doi.org/10.5114/bta.2022.120709 Text en © 2022 Institute of Bioorganic Chemistry, Polish Academy of Sciences https://creativecommons.org/licenses/by-nc-nd/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), allowing third parties to download and share its works but not commercially purposes or to create derivative works. |
spellingShingle | Review Papers Krasnopolsky, Yuriy Pylypenko, Daria Licensed liposomal vaccines and adjuvants in the antigen delivery system |
title | Licensed liposomal vaccines and adjuvants in the antigen delivery system |
title_full | Licensed liposomal vaccines and adjuvants in the antigen delivery system |
title_fullStr | Licensed liposomal vaccines and adjuvants in the antigen delivery system |
title_full_unstemmed | Licensed liposomal vaccines and adjuvants in the antigen delivery system |
title_short | Licensed liposomal vaccines and adjuvants in the antigen delivery system |
title_sort | licensed liposomal vaccines and adjuvants in the antigen delivery system |
topic | Review Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837556/ https://www.ncbi.nlm.nih.gov/pubmed/36685697 http://dx.doi.org/10.5114/bta.2022.120709 |
work_keys_str_mv | AT krasnopolskyyuriy licensedliposomalvaccinesandadjuvantsintheantigendeliverysystem AT pylypenkodaria licensedliposomalvaccinesandadjuvantsintheantigendeliverysystem |